NVIGEN, a leading provider of modern nanoparticle solutions to empower revolutionary personalized healthcare, announces its new application in RNA sequencing (RNAseq) that promises to transform our understanding of cellular dynamics within tissues.
Single-cell transcriptomics have opened new frontiers in biology by allowing researchers to unravel the intricate web of gene expression within individual cells. However, acquiring high-quality single-cell sequencing data from tissue has long been a challenge. Existing techniques often require laborious manual cell isolation procedures that can introduce biases and limit the capture of truly representative cell populations.
NVIGEN’s new approach towards single cell RNAseq of tissue samples shatters these limitations. Leveraging cutting-edge magnetic nanoparticle capture technology, NVIGEN has developed a highly sensitive workflow to obtain high quality RNAseq data from minuscule aspirations of ~1% of a single cell’s contents using the fully automated nanopipette technology developed at Prof. Nader Pourmand’s lab at UCSC Biomolecular Engineering and Genome Technology Center.*
NVIGEN NERNST-Seq: Nanoparticle Enhanced RNA Spatial and Temporal Sequencing
“By combining fully automated nanopipettes with NVIGEN’s highly sensitive magnetic nanoparticle capture, we have pioneered a game-changing innovation that obviates the need for manual cell manipulation and isolation,” Said Prof. Pourmand, “This breakthrough enables researchers to obtain high-quality sequencing reads from individual cells within intact tissue, ensuring unparalleled accuracy and precision in RNAseq.”
NVIGEN’s magnetic nanoparticle capture is poised to usher in a new era in tissue RNAseq. One of the most remarkable features of this approach is the ability to provide not only spatial but also temporal resolution. Researchers can now sample individual cells multiple times, capturing longitudinal information that was previously unattainable.
“This breakthrough opens the door to a deeper understanding of dynamic cellular processes,” Said Dr. Aihua Fu, cofounder and chief executive officer of NVIGEN, “We greatly appreciate the opportunity to collaborate with Prof. Pourmand and the funding support from NIH/NCI SBIR. This has the potential to accelerate discoveries in fields of cancer research, developmental biology, and regenerative medicine, among others. We have launched a specific product line named NERNST-Seq™: Nanoparticle Enhanced RNA Spatial & Temporal Sequencing, to facilitate the commercialization of these exciting applications.”
Source – PRNewswire